‍

Know about HPV+ oropharyngeal and anal cancer recurrence earlier and more accurately.

Don't miss the opportunity to intervene early.

Imaging and clinical exams can miss early signs of oropharyngeal and anal cancer recurrence^1,2

Red icon of a calendar, with no dates filled in — ‍

Within 5 years of treatment, cancer recurs for up to 1 in 4 HPV+ oropharyngeal cancer and 1 in 3 HPV+ anal cancer patients^3,4,5

Up to one half of first recurrences for oropharyngeal are in a new part of the body (distant metastasis)⁶

HPV+ oropharyngeal and anal cancer recurrence can be detected over a year before symptoms appear with NavDx testing^4,7

The NavDx test is the first and most clinically validated blood test that aids in the early detection of HPV-driven cancer

Detecting recurrence early, when disease burden is low, may improve a patient’s chances of long-term survivorship^6,9,10

Man and doctor talking. Red text: "no insight?" / Teal text: "know the insights" — ‍

Know The Status.

Published studies show NavDx testing accurately and reliably predicted recurrence of oropharyngeal and anal cancer.^4,8

Order a test

For patients with HPV+ oropharyngeal cancer

≥ 95%

of people with one positive test had cancer recur (PPV)

≥ 98%

of people who routinely tested negative had no cancer recurrence (NPV)

For patients with HPV+ anal cancer

≥ 96%

of people with one positive test had cancer recur (PPV)

≥ 92.5%

of people who routinely tested negative had no cancer recurrence (NPV)

Industry-leading turnaround time. No need for baseline testing.

Want more details?

Do you have any questions about the NavDx test? We’re here to help. Fill out the form and a Naveris Product Development Representative will contact you.

*First Name

*Last Name

*Zip/Postal Code

*Email

Phone

Hospital or Institution Name

*I am a:

Notes

Submit